Novo Nordisk Dives After Medicare Targets Ozempic, Wegovy For Price Cuts
Novo Nordisk stock tumbled Friday after its weight-loss drug Wegovy landed on Medicare's next list of drugs to face price negotiations.
Some parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.
Novo Nordisk stock tumbled Friday after its weight-loss drug Wegovy landed on Medicare's next list of drugs to face price negotiations.